Uterine @entity1377 (UPSC) affects 1% to 10% of @entity1 with @entity1478 . UPSC is more @entity146 than conventional @entity1204 because UPSC presents with @entity1442 , similar to @entity43 . There are several biomarkers for UPSC, which indicate that the pathogenesis of this condition is different than epithelial ovarian and conventional @entity1204 . There are no risk factors for UPSC. Extended surgical staging is the optimal surgical approach for @entity1 without known distant metastases. @entity1 with stage IA disease do not benefit from further adjuvant therapy. Adjuvant pelvic radiotherapy reduces pelvic relapse in intermediate- and high-risk @entity1 ( @entity5 ) and extends survival rates of @entity1 when administered with chemotherapy. In this setting, chemotherapy (with or without adjuvant radiotherapy) is a @entity902 -based regimen, combined with @entity632 and @entity786 . A newer regimen is @entity1311 , with or without @entity902 . An alternative approach for treating @entity1 with UPSC has been to use whole abdominal radiotherapy. The results of Gynecologic Oncology Group protocol 122, which involves @entity1 with UPSC who are being treated with chemotherapy and whole abdominal radiotherapy, are expected to reveal a minimal difference between these arms in overall survival rates. In @entity1 experiencing distant or extensive abdominal relapse, management has been palliative, using @entity902 -based regimens or single-agent therapy to assess response. Treatment for @entity1 with further relapse must be individualized because there are no studies addressing these scenarios. Palliative radiotherapy should be offered to @entity1 needing symptom control for metastatic or progressive @entity66 . Many of these @entity1 face a significant risk of treatment failure and death because of distant relapse. Therefore, the use of randomized trials to evaluate new therapies is critical.

Therapeutic dilemmas in the management of uterine XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary serous carcinoma'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity43 :: ('MESH:D010051', 'Disease') :: ['epithelial ovarian cancer'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity66 :: ('MESH:D004194', 'Disease') :: ['local disease'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage IC, II, and III disease'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity1478 :: ('MESH:D014591', 'Disease') :: ['endometrial malignancies'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity1377 :: (MESH:D002291,Disease) :: ['papillary serous carcinoma']
